The recent data with blinatumomab, CAR T-cell therapy and menin inhibitors in infantile KMT2A-r B-ALL have shown astounding improvement in outcomes in this otherwise challenging disease subset. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.